Long-Term Follow-Up Study for Subjects Treated With P-BCMA-101
Status:
Enrolling by invitation
Trial end date:
2032-11-01
Target enrollment:
Participant gender:
Summary
Subjects are enrolled in this study following completion or early discontinuation from a
Poseida sponsored or supported study of P-BCMA-101 T cells and will be followed for a total
of 15 years post treatment from the last P-BCMA-101 treatment. Subjects will be monitored for
safety and efficacy to assess the risk of delayed adverse events (AEs) and assess long-term
efficacy, and PK and quantification of P-BCMA-101 T cells. Rimiducid may be administered as
indicated.
Phase:
Phase 1
Details
Lead Sponsor:
Poseida Therapeutics, Inc.
Collaborator:
California Institute for Regenerative Medicine (CIRM)